Valuation: Linc AB

Market Cap 4.11B 427M 373M 344M 317M 600M 41.09B 610M 1.61B 20.08B 1.6B 1.57B 69.22B P/E 2024
3.84x
P/E 2025 -10.1x
Enterprise Value 3.83B 398M 348M 321M 295M 558M 38.25B 568M 1.5B 18.7B 1.49B 1.46B 64.44B EV / Sales 2024
3.45x
EV / Sales 2025 -9.06x
Free-Float
36.64%
Yield 2024 *
-
Yield 2025 -
1 day-1.11%
1 week+1.43%
Current month-0.14%
3 months-7.67%
6 months+10.94%
Current year+1.87%
1 week 69.9
Extreme 69.9
72.5
1 month 66.6
Extreme 66.6
73.7
Current year 58.9
Extreme 58.9
78.1
1 year 58.9
Extreme 58.9
83.6
3 years 52.2
Extreme 52.2
103.4
5 years 43.8
Extreme 43.8
109.9
10 years 43.8
Extreme 43.8
118.2
Manager TitleAgeSince
Chief Executive Officer 52 2019-12-31
Director of Finance/CFO 44 2019-12-31
Director TitleAgeSince
Chairman 73 1990-12-31
Director/Board Member 52 2019-12-31
Director/Board Member 60 2019-12-31
Date Insider Type Main position Quantity % Market Cap.
04-27Buy

Director

3,000 0.0052%
04-27Buy

Director

20,000 0.0345%
04-24Buy

Director

9,000 0.0155%
Change 5-day change 1-year change 3-year change Capi.($)
-1.11%+1.43%-8.51%+17.55% 427M
+1.99%+3.36%+12.41%-3.75% 157M
Average +0.44%+1.38%+1.95%+6.90% 292.19M
Weighted average by Cap. -0.28%+1.41%-2.87%+11.81%

Financials

2024 2025
Net sales 1.29B 134M 117M 108M 99.42M 188M 12.9B 192M 507M 6.31B 504M 493M 21.74B -414M -43M -37.59M -34.68M -31.88M -60.4M -4.14B -61.43M -162M -2.02B -161M -158M -6.97B
Net income 1.3B 135M 118M 109M 100M 190M 13.01B 193M 511M 6.36B 508M 497M 21.91B -400M -41.51M -36.29M -33.48M -30.77M -58.31M -3.99B -59.3M -157M -1.95B -156M -152M -6.73B
Net Debt -550M -57.09M -49.91M -46.04M -42.32M -80.19M -5.49B -81.56M -216M -2.68B -214M -210M -9.25B -284M -29.49M -25.79M -23.79M -21.87M -41.43M -2.84B -42.14M -111M -1.39B -111M -108M -4.78B
Logo Linc AB
Linc AB is a Sweden-based investment company. Linc invests in product-oriented companies within the Nordic Life Science industry - primarily in pharmaceutical and medical technology companies. The investments are made in both private and public companies and in research and operational companies. Typically, investments in drug development take place in an earlier phase compared to investments in medical technology. Linc Invest is an active and long-term owner with a wide industrial network to support the portfolio companies. The Company works together with the management, founders and board to realize the inherent potential that exists in the investment, have ambitious plans for further development and expansion and actively participate in the nomination committee work.
Employees
2
Date Price Change Volume
26-07-15 SEK 71.00 -1.11% 28,240
26-07-14 SEK 71.80 +1.56% 25,881
26-07-13 SEK 70.70 +0.43% 10,763
26-07-10 SEK 70.40 -1.54% 18,602
26-07-09 SEK 71.50 +2.14% 34,221
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
71.00SEK
Average target price
71.00SEK
Spread / Average Target
0.00%
  1. Stock Market
  2. Stocks
  3. LINC Stock